Publication: The function and significance of SERA2a in congestive heart failure: an analysis of gene therapy trials
Authors
Wu, Pei ; Zhai, Yuting ; Li, Dongye
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de BiologĂa Celular e HistologĂa
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-11-878
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Congestive heart failure (CHF) is a
widespread disease that has a negative impact on health,
worldwide. Despite advances in therapies, morbidity,
mortality and hospital discharges due to CHF remain
high. Advances in the understanding of the pathophysiological mechanisms of CHF and the development
of gene transfer technology have made gene therapy a
realistic potential therapeutic method for CHF. Among
the various potential targets, sarco-endoplasmic
reticulum Ca2+-ATPase 2a (SERCA2a), which is an
important protein in the regulation of Ca2+ cycling, has
piqued the interest of many researchers. Restoring
decreased SERCA2a activity in CHF could improve
cardiac contractions and energetics, as well as reducing
myocardial fibrosis and ventricular arrhythmias, and
these benefits have been confirmed by studies using both
in vivo and in vitro models. Following these promising
preclinical results, SERCA2a gene therapy advanced to
clinical trials. However, results of the clinical trials were
controversial, leading some to question whether
SERCA2a is the right target for CHF treatment. In this
review, we illustrate the function and significance of
SERCA2a in CHF, and more importantly, analyze
possible causes of the controversial clinical trials results,
with the aim of stimulating future research on the
relationship between SERCA2a and CHF.
publication.page.subject
Citation
Histology and Histopathology, Vol.32, nÂş8, (2017)
item.page.embargo
Ir a EstadĂsticas
Este Ătem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/